Frequently Asked Questions on the Emergency Use Authorization for Bamlanivimab and Etesevimab

As of January 24, 2022, due to the high frequency of the Omicron variant, bamlanivimab and etesevimab, administered together, are not currently authorized for use in any U.S. region because of markedly reduced activity against the omicron variant. Therefore, these drugs may not be administered for treatment or post-exposure prevention of COVID-19 under the Emergency Use Authorization until further notice by the Agency. FDA will continue to closely monitor the SARS-CoV-2 variants using resources such as the CDC's Variant website, and will determine whether use in a geographic region is consistent with the scope of authorization for bamlanivimab and etesevimab, administered together. FDA's determination and any updates will be available at Emergency Use Authorizations for Drugs and Non-Vaccine Biological Products.

Q. What is an Emergency Use Authorization (EUA)?
A: Under section 564 of the Federal Food, Drug & Cosmetic Act, after a declaration by the HHS Secretary based on one of four types of determinations, FDA may authorize an unapproved product or unapproved uses of an approved product for emergency use. In issuing an EUA, FDA must determine, among other things, that based on the totality of scientific evidence available, including data from adequate and well-controlled clinical trials, if available, it is reasonable to believe that the product may be effective in diagnosing, treating, or preventing a serious or life-threatening disease or condition caused by a chemical, biological, radiological, or nuclear agent; that the known and potential benefits, when used to treat, diagnose or prevent such disease or condition, outweigh the known and potential risks for the product; and that there are no adequate, approved, and available alternatives. Emergency use authorization is NOT the same as FDA approval or licensure.

Q. What does this EUA authorize? What are the limitations of authorized use?
A. The EUA authorizes Eli Lilly and Company’s (Lilly’s) bamlanivimab and etesevimab, administered together, for emergency use for both treatment and as post-exposure prophylaxis for prevention of COVID-19.

Treatment

Treatment of mild-to-moderate COVID-19 in adults and pediatric patients, including neonates (babies who are four weeks old or younger), with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death.

Limitations of Authorized Use for Treatment

- Bamlanivimab and etesevimab are not authorized for treatment of mild-to-moderate COVID-19 in geographic regions where infection is likely to have been caused by a non-susceptible SARS-CoV-2 variant based on available information including variant susceptibility to these drugs and regional variant frequency.
  - FDA will monitor conditions to determine whether use in a geographic region is consistent with this scope of authorization, referring to available information, including information on variant susceptibility [see Microbiology/Resistance Information (15) in the Fact Sheet for Health Care Providers], and CDC regional variant frequency data.
FDA’s determination and any updates will be available at Emergency Use Authorizations for Drugs and Non-Vaccine Biological Products.

- Bamlanivimab and etesevimab are not authorized for use in adult and pediatric patients 2 years and older who are hospitalized due to COVID-19.
  - The reasons for hospital admission may be different and the threshold for hospital admission may be lower for neonates, young infants and toddlers with COVID-19 compared to older children and adults. The authorization covers young children (i.e., birth to 2 years of age) who are hospitalized with mild to moderate COVID-19 at the time of treatment to receive bamlanivimab and etesevimab.
- Bamlanivimab and etesevimab are not authorized for use in patients, regardless of age, who:
  - require oxygen therapy and/or respiratory support due to COVID-19, OR
  - require an increase in baseline oxygen flow rate and/or respiratory support due to COVID-19 and are on chronic oxygen therapy and/or respiratory support due to underlying non-COVID-19 related comorbidity.
- Treatment with bamlanivimab and etesevimab has not been studied in patients hospitalized due to COVID-19. Monoclonal antibodies, such as bamlanivimab and etesevimab, may be associated with worse clinical outcomes when administered to hospitalized patients with COVID-19 requiring high flow oxygen or mechanical ventilation.

**Post-Exposure Prophylaxis (Prevention)**

For use as post-exposure prophylaxis for prevention of COVID-19 in adult and pediatric individuals, including neonates, who are at high risk of progression to severe COVID-19, including hospitalization or death, and are:

- not fully vaccinated or who are not expected to mount an adequate immune response to complete SARS-CoV-2 vaccination (for example, individuals with immunocompromising conditions including those taking immunosuppressive medications) and
  - have been exposed to an individual infected with SARS-CoV-2 consistent with close contact criteria per Centers for Disease Control and Prevention (CDC) or
  - who are at high risk of exposure to an individual infected with SARS-CoV-2 because of occurrence of SARS-CoV-2 infection in other individuals in the same institutional setting (for example, nursing homes and prisons)

In general, people are considered fully vaccinated two weeks after their second dose in a two dose series (the Pfizer or Moderna vaccines) OR two weeks after a single-dose vaccine (the Janssen vaccine).

The CDC defines close contact as someone who has been within six feet of an infected person (laboratory-confirmed or a clinically compatible illness) for a cumulative total of 15 minutes or more over a 24-hour period.

**Limitations of Authorized Use for Post-Exposure Prophylaxis**

- Bamlanivimab and etesevimab are not authorized for post-exposure prophylaxis of COVID-19 in geographic regions where exposure is likely to have been to a non-susceptible SARS-CoV-2 variant, based on available information including variant susceptibility to these drugs and regional variant frequency.
FDA will monitor conditions to determine whether use in a geographic region is consistent with this scope of authorization, referring to available information, including information on variant susceptibility [see Microbiology/Resistance Information (15) in the Fact Sheet for Health Care Providers], and CDC regional variant frequency data. FDA’s determination and any updates will be available at Emergency Use Authorizations for Drugs and Non-Vaccine Biological Products.

- Post-exposure prophylaxis with bamlanivimab and etesevimab is not a substitute for vaccination against COVID-19. FDA has authorized three vaccines, and approved two, to prevent COVID-19 and serious clinical outcomes caused by COVID-19, including hospitalization and death. FDA urges you to get vaccinated, if you are eligible. Learn more about FDA-authorized COVID-19 vaccines. Find a COVID-19 vaccine near you at vaccines.gov.

- Bamlanivimab and etesevimab are not authorized for pre-exposure prophylaxis for prevention of COVID-19.

**Q. Why has FDA not revoked the authorization for bamlanivimab and etesevimab, administered together, due to the omicron variant?**

A. FDA may revoke an EUA if, for example, the statutory criteria for authorization under section 564(c) of the Federal Food, Drug, and Cosmetic Act are no longer met. The Agency recognizes that bamlanivimab and etesevimab, administered together, may retain activity against future circulating SARS-CoV-2 variants other than the Omicron variant, and that the pattern of circulating variants of SARS-CoV-2 throughout the United States may also shift over time.

Based on the totality of scientific evidence available at this time, FDA has determined that the statutory criteria continue to be met, including that the known and potential benefits of bamlanivimab and etesevimab, administered together, outweigh the known and potential risks when used consistent with the terms and conditions of the authorization to:

- treat a patient with mild-to-moderate COVID-19 likely caused by a variant that is susceptible to this therapy, or
- when used as post-exposure prophylaxis of COVID-19 in an individual likely exposed to a susceptible variant to this therapy.

As such, FDA is not revoking the authorization for bamlanivimab and etesevimab, administered together, at this time, but is instead limiting the authorization of use.

**Q. How is high risk defined under the EUA?**

A. The following medical conditions or other factors may place adults and pediatric patients, including neonates, at higher risk for progression to severe COVID-19:

- Older age (for example age ≥65 years of age)
- <1 year old
- Obesity or being overweight
- Pregnancy
- Chronic kidney disease
- Diabetes
- Immunosuppressive disease or immunosuppressive treatment
H. Cardiovascular disease (including congenital heart disease) or hypertension
I. Chronic lung diseases (for example, chronic obstructive pulmonary disease, asthma [moderate-to-severe], interstitial lung disease, cystic fibrosis and pulmonary hypertension)
J. Sickle cell disease
K. Neurodevelopmental disorders (for example, cerebral palsy) or other conditions that confer medical complexity (for example, genetic or metabolic syndromes and severe congenital anomalies)
L. Having a medical-related technological dependence (for example, tracheostomy, gastrostomy, or positive pressure ventilation (not related to COVID-19))

Other medical conditions or factors (for example, race or ethnicity) may also place individual patients at high risk for progression to severe COVID-19 and authorization of bamlanivimab and etesevimab under the EUA is not limited to the medical conditions or factors listed above. For additional information on medical conditions and factors associated with increased risk for progression to severe COVID-19, see the CDC website: People with Certain Medical Conditions. Health care providers should consider the benefit-risk for an individual patient.

Q. Bamlanivimab and etesevimab administered together are authorized for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients, including neonates, with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death. What does direct SARS-CoV-2 viral testing mean?
A. Direct SARS-CoV-2 viral tests diagnose active COVID-19 infection. Direct SARS-CoV-2 viral tests include two types of diagnostic tests for COVID-19:
   1. Molecular tests, such as RT-PCR tests, that detect the virus’s genetic material
   2. Antigen tests that detect specific proteins from the virus

Antibody tests should not be used to diagnose COVID-19 and are not direct SARS-CoV-2 viral tests. Antibody tests look for antibodies made by the immune system in response to the SARS-CoV-2 virus.

Q. What data supported the Agency’s determination that bamlanivimab and etesevimab, administered together, would not retain activity against the Omicron variant?
A. As conditions to the EUA for bamlanivimab and etesevimab, Lilly is required to monitor and test the activity of bamlanivimab and etesevimab against variants of the virus that cause COVID-19. For the Omicron variant, Lilly submitted testing data to FDA.

The authorized monoclonal antibodies need to bind to the spike protein of the virus in order to neutralize the virus. Following the emergence of the Omicron variant, Lilly assessed the activity of their product(s) against this variant and submitted these data to the FDA for review. Neutralization assays using virus-like particles (VLP) expressing SARS-CoV-2 spike proteins showed that bamlanivimab and etesevimab had marked reductions in neutralization activity. Specifically, the ability of bamlanivimab and etesevimab to neutralize VLPs expressing the spike protein of the Omicron variant was dramatically lower as compared to that of VLPs expressing the spike protein from the original strain of the virus. Using a measurement called neutralization, there was greater than 1000 fold reduction in the activity. These data are shown in Section 15 of the Health Care Provider Fact Sheet.
Q. How can bamlanivimab and etesevimab be obtained for use under the EUA?
A. For questions on how to obtain bamlanivimab and etesevimab, or etesevimab alone to pair with an existing supply of bamlanivimab under current distribution procedures, please contact COVID19therapeutics@hhs.gov.

Q. Are bamlanivimab and etesevimab monoclonal antibodies? What is a monoclonal antibody?
A. Yes, bamlanivimab and etesevimab are monoclonal antibodies. Monoclonal antibodies are laboratory-produced molecules engineered to serve as substitute antibodies that can restore, enhance or mimic the immune system's attack on pathogens. Bamlanivimab and etesevimab are designed to block viral attachment and entry into human cells, thus neutralizing the virus.

Q. When should bamlanivimab and etesevimab be administered to a patient?
A. For treatment, bamlanivimab and etesevimab are administered together as a single intravenous infusion. It is recommended that bamlanivimab and etesevimab be administered as soon as possible after positive viral test for SARS-CoV-2 and within 10 days of symptom onset.

For post-exposure prophylaxis, bamlanivimab and etesevimab should be administered together as a single intravenous infusion as soon as possible following exposure to SARS-CoV-2.

More information about administration for treatment and post-exposure prophylaxis is available in the Fact Sheet for Health Care Providers.

Q: Does “within 10 days of symptom onset” mean that a patient should have shown symptoms to receive bamlanivimab and etesevimab administered together for its treatment use?
A. Yes. Symptom onset is the point at which a patient starts exhibiting symptoms. Patients should be treated as soon as possible after a positive viral test for SARS-CoV-2 and within ten days of COVID-19 symptom onset. If a patient has a positive viral test for SARS-CoV-2 but does not show symptoms, they do not meet the definition of mild-to-moderate disease.
Patients with mild-to-moderate COVID-19 are those patients who are actively exhibiting certain symptoms of COVID-19 illness (such as, fever, cough, sore throat, headache, malaise, muscle pain, nausea, vomiting, diarrhea, loss of taste and smell).

For more information on mild-to-moderate COVID-19, refer to the National Institutes of Health’s website at: Clinical Spectrum | COVID-19 Treatment Guidelines (nih.gov).

Therefore, patients who are at high risk for progression to severe COVID-19, including hospitalization or death, with mild-to-moderate COVID-19 disease (i.e., symptoms consistent with mild-to-moderate illness at the time of treatment) and who are within 10 days of symptom onset are within the scope of the EUA.

Q. Are bamlanivimab and etesevimab approved by the FDA to treat COVID-19?
A. No. They are not currently FDA-approved to treat any diseases or conditions, including COVID-19. Bamlanivimab and etesevimab are investigational drugs.

Q. Does the EUA permit the use of bamlanivimab and etesevimab as authorized in patients hospitalized for reasons other than COVID-19?

1/31/2022
A. Bamlanivimab and etesevimab, administered together, are authorized for emergency use for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients, including neonates, with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death. If a patient is hospitalized for reasons other than COVID-19, such as for an elective orthopedic procedure for example, and the patient reports mild to moderate symptoms of COVID-19, confirmed with positive results of a direct SARS-CoV-2 viral test, then it may be appropriate to treat the patient with bamlanivimab and etesevimab, administered together, if the patient is also at high risk for progression to severe COVID-19, including hospitalization or death and the terms and conditions of the authorization are met, as detailed in the Fact Sheet for Health Care Providers.

Q. Are there data showing treatment with bamlanivimab and etesevimab, administered together, might benefit patients with mild-to-moderate COVID-19? Or as post-exposure prophylaxis of COVID-19?

A. Yes. The strongest evidence supporting the issuance of this EUA for bamlanivimab and etesevimab, administered together, as treatment comes from the phase 3 portion of a randomized, double-blind, placebo-controlled clinical trial (BLAZE-1) in 769 non-hospitalized adults with mild-to-moderate COVID-19 symptoms who were at high risk for progression to severe COVID-19. Of these patients, 511 received a single infusion of bamlanivimab 700 mg and etesevimab 1,400 mg together and 258 received placebo. The primary endpoint was COVID-19 related hospitalizations or death by any cause during 29 days of follow-up. Hospitalization or death occurred in 15 (6%) patients who received placebo compared to 4 (0.8%) patients treated with bamlanivimab 700 mg and etesevimab 1,400 mg administered together (p<0.001), an 87% reduction. All deaths (n = 4, 1.6%) occurred in the placebo group. Thus, all-cause mortality was significantly lower in the bamlanivimab 700 mg and etesevimab 1,400 mg group than the placebo group (p=0.01). In addition, patients that received bamlanivimab 700 mg and etesevimab 1,400 mg together had a faster time to symptom resolution in the clinical trial.

The primary data supporting the post-exposure prophylaxis of COVID-19 are from the Phase 3 trial BLAZE-2. BLAZE-2 Part 1 is a randomized, double-blind, placebo-controlled study evaluating bamlanivimab alone for prevention of COVID-19 in residents and staff of skilled nursing facilities following a confirmed reported case of SARS-CoV-2 infection at the facility. All participants in Part 1 were randomized and treated with a single infusion of bamlanivimab 4,200 mg or placebo. Results of baseline testing for SARS-CoV-2 were not known until after the therapy was administered. Those with a positive baseline SARS-CoV-2 RT-PCR test were included in the treatment population (N=132) and those with a negative test were included in the prevention population (N=966). The primary endpoint (cases of symptomatic COVID-19 by Day 57) was assessed after all participants in the prevention population reached 8 weeks of follow-up, and analysis were adjusted for facility, sex, and role within facility (resident/staff). The treatment population was analyzed separately and not included in the primary endpoint for this prevention trial.

In the prevention population, there were 114 cases of symptomatic COVID-19, with a lower frequency occurring in participants treated with bamlanivimab as compared to placebo (residents and staff; adjusted odds ratio 0.43; p<0.001) reducing the risk of being infected with COVID-19 by up to 57%. For the pre-specified subgroup of nursing home residents, there were 45 cases of symptomatic COVID-19, with a lower frequency in those treated with bamlanivimab versus placebo (adjusted odds ratio 0.20; p<0.001), reducing the risk of being infected with COVID-19 by up to 80%. For the post-hoc subgroup of patients who met the high-risk criteria (all residents and all high-risk staff), there were 75 cases of
symptomatic COVID-19, with a lower frequency in those treated with bamlanivimab versus placebo (adjusted odds ratio 0.28; nominal p<0.001), reducing the risk of being infected with COVID-19 by up to 72%.

While BLAZE-2 only evaluated dosing with bamlanivimab alone, it is reasonable to expect that bamlanivimab and etesevimab, administered together, may be safe and effective for post-exposure prophylaxis based on:

- Bamlanivimab and etesevimab, administered together, showed a statistically significant reduction in progression of severe COVID-19, including hospitalization or death, in high-risk patients with mild-to-moderate COVID-19 (Phase 3 data from BLAZE-1 treatment trial).
- Nonclinical and clinical data support that bamlanivimab and etesevimab, administered together, will provide an advantage over bamlanivimab alone against certain SARS-CoV-2 viral variants.

A total of 125 non-hospitalized pediatric subjects with mild-to-moderate COVID-19 symptoms and were high risk for progression to severe COVID-19 in the Phase 3 portion of BLAZE-1. Pediatric patients weighing 40 kg or more received the same dose as adults (700 mg bamlanivimab and 1,400 mg etesevimab), while those weighing less than 40 kg received weight-based dosing.

Of the 125 pediatric subjects, 33 subjects ages 12 to <18 were evaluated in double-blind, placebo-controlled Phase 3 cohorts of BLAZE-1, and 1 subject age 12 to <18 was evaluated in a controlled addendum to BLAZE-1. Of the 33 pediatric subjects, 14 received placebo, while 19 received the authorized dose or a higher dose for their age, and 5 received a lower dose than authorized for their age. A total of 91 pediatric subjects were evaluated in an open-label addendum to BLAZE-1, with 40 subjects ages 12 to <18, 36 ages 6 to <12, 10 ages 2 to <6, and 5 ages 0 to <2. The youngest participant was 10 months of age and weighed 8.6 kg. Bamlanivimab and etesevimab was well tolerated in these participants, with a safety profile similar to adults. Because only limited numbers of children were enrolled in the placebo-controlled portion of BLAZE-1, efficacy relative to a placebo was not determined.

The efficacy extrapolation for pediatric patients was supported by similarities in pathogenesis, the course of the disease, and the effect of the drugs when comparing pediatric patients and adults. The drug exposure in children ≥ 2 years or weighing > 12 kg who were administered the authorized dose were comparable to those observed in adults administered the authorized dose. Using pharmacokinetic modeling and simulation, the drug exposure in children < 2 years or weighing ≤ 12 kg who are administered the authorized dose is expected to match the exposure observed in adults at the authorized dose. Additionally, viral load reduction was comparable between pediatrics and adult patients administered the authorized dose.

Details on the clinical trial results can be found in Section 18 of the authorized Fact Sheet for Health Care Providers.

Q. Are there side effects of bamlanivimab and etesevimab?
A. Approximately 1,400 non-hospitalized subjects have received bamlanivimab and etesevimab administered together in clinical trials at doses of bamlanivimab 700 mg and etesevimab 1,400 mg or higher. Bamlanivimab and etesevimab at the authorized doses of 700 mg and 1,400 mg have been administered together to approximately 800 subjects.
Serious hypersensitivity reactions, including anaphylaxis and fainting (vasovagal), have been observed with administration of bamlanivimab and etesevimab. In clinical trials, these reactions have been rare, but may be severe or life threatening.

Based on reporting of adverse events that occurred after administration of bamlanivimab alone under EUA, clinical worsening of COVID-19 after administration of bamlanivimab has been reported and may include signs or symptoms of fever, hypoxia or increased respiratory difficulty, arrhythmia (e.g., atrial fibrillation, sinus tachycardia, bradycardia), fatigue, and altered mental status. Some of these events required hospitalization. It is not known if these events were related to bamlanivimab use or were due to progression of COVID-19.

Nausea, dizziness, and pruritus were the most commonly reported adverse events after administration of bamlanivimab and etesevimab together.

The side effect profile in pediatric subjects in the clinical trial was similar to that observed in adults.

Q. Are bamlanivimab and etesevimab co-packaged?
A. At this time, bamlanivimab is not co-packaged with etesevimab under this EUA. While these products are not co-packaged, etesevimab cannot be used alone and must be administered with bamlanivimab. Bamlanivimab also cannot be used alone as this use is no longer authorized. Bamlanivimab and etesevimab must be administered together.

Q. Are there reporting requirements for health care facilities and providers as part of the EUA?
A. Yes. As part of the EUA, FDA requires health care providers who prescribe bamlanivimab and etesevimab together to report all medication errors and serious adverse events considered to be potentially related to bamlanivimab and etesevimab through FDA’s MedWatch Adverse Event Reporting program. Providers can complete and submit the report online; or download and complete the form, then submit it via fax at 1-800-FDA-0178. This requirement is outlined in the EUA’s health care provider Fact Sheet.

Health care facilities and providers must report therapeutics information and utilization data as directed by the U.S. Department of Health and Human Services.

Q. Do patient outcomes need to be reported under the EUA?
A. No, reporting of patient outcomes is not required under the EUA. However, reporting of all medication errors and serious adverse events considered to be potentially related to bamlanivimab and etesevimab, administered together, occurring during treatment is required.

Q. Does the EUA authorize bamlanivimab and etesevimab, administered together, to be used as pre-exposure prophylaxis for prevention of COVID-19?
A. No. Bamlanivimab and etesevimab, administered together, are not authorized to be used for pre-exposure prophylaxis for prevention of COVID-19.

Q. Can health care providers share the patient/caregiver Fact Sheet electronically?
A. Electronic delivery of the Fact Sheet is permitted under the EUA for bamlanivimab and etesevimab. For example, when the patient requests the Fact Sheet electronically, it can be delivered as a PDF prior
to medication administration. Health care providers should confirm receipt of the Fact Sheet with the patient.

Q. Is there likely to be an increased risk of infusion-related reactions with shorter versus longer infusion times?
A. FDA does not anticipate an increased risk of infusion-related reactions with the shorter infusion times or use of different size saline bags for dilution authorized. The preparation and administration instructions, including the shorter durations of infusion with smaller volumes of diluent were based on data evaluated by FDA including product quality data and data from clinical trials.

Q. Can I receive a COVID-19 vaccine if I was treated with a monoclonal antibody for COVID-19?
A. Health care providers should refer to recommendations of the Advisory Committee on Immunization Practices regarding vaccination.

Q. Has FDA authorized an extension to the shelf-life of bamlanivimab and etesevimab beyond the labeled expiration date?
A. FDA has authorized an extension to the shelf-life of bamlanivimab and etesevimab following a thorough review of data submitted by Eli Lilly and Company. This extension applies to all unopened vials of bamlanivimab and etesevimab that have been held in accordance with storage conditions (refrigeration at a temperature of 2°C to 8°C (36°F to 46°F) detailed in the authorized Fact Sheet for Health Care Providers and the Letter of Authorization for Emergency Use Authorization (EUA) 094 for bamlanivimab and etesevimab, administered together.

Bamlanivimab and etesevimab, authorized to be administered together under the EUA, have fixed expiration dates on the label of each vial and carton. The shelf-life of unopened vials of bamlanivimab and etesevimab can be confirmed using the batch number. The batch numbers are available on the Drug and Biological Therapeutic Products Emergency Use Authorization website under the bamlanivimab and etesevimab section. This site includes a complete listing of extended expiration dates by batch number. If the batch number on the vial/carton is not included in this listing, the product is labeled with the correct expiration date.

Q. Can a child receive bamlanivimab and etesevimab if they were exposed to COVID-19 at school?
A. Yes. Health care providers should assess exposure risk when considering whether administration of bamlanivimab and etesevimab for post-exposure prophylaxis for prevention of COVID-19 is appropriate for a particular pediatric patient.

Bamlanivimab and etesevimab are authorized for post-exposure prophylaxis for prevention of COVID-19 in individuals who are high risk for progression to severe COVID-19, including hospitalization or death and are:

- not fully vaccinated or who are not expected to mount an adequate immune response to complete SARS-CoV-2 vaccination (for example, individuals with immunocompromising conditions including those taking immunosuppressive medications) and
- have been exposed to an individual infected with SARS-CoV-2 consistent with close contact criteria per Centers for Disease Control and Prevention (CDC) or
• who are at high risk of exposure to an individual infected with SARS-CoV-2 because of occurrence of SARS-CoV-2 infection in other individuals in the same institutional setting (for example, nursing homes and prisons)

In general, people are considered fully vaccinated two weeks after their second dose in a two dose series (the Pfizer or Moderna vaccines) OR two weeks after a single-dose vaccine (the Janssen vaccine).

The CDC defines close contact as someone who has been within six feet of an infected person (laboratory-confirmed or a clinically compatible illness) for a cumulative total of 15 minutes or more over a 24-hour period.